Five Companies Transforming the Future of Breast Cancer Care

Palm Beach, FL – February 26, 2020  – When caught early enough, the five-year survival rates are 99%, says the American Cancer Society.  However, early detection is essential, which is why experts strongly advised screening.  After all, “Where the breast cancer is located, where it has spread to, how big it is—all that plays a role in different treatment options for patients,” says Dr. Keith Wells, a medical oncologist at Willamette Valley Cancer Institute, as quoted by KVAL13.  To assist patients, companies are racing to produce cost-effective screening methods that offer greater accuracy, speed, and comfort than traditional methods.  As you might expect, the market for breast imaging with existing methods has been big.  In fact, according to Meticulous Research, the global breast imaging market will be worth up to $5.13 billion, growing at a CAGR of 8.2% over the next four years.  Some of the top companies leading the fight for better cancer detection include Izotropic Corporation (CSE:IZO)(OTCPK:IZOZF), Hologic Inc. (NASDAQ:HOLX), Stryker Corporation (NYSE:SYK), NeGenomics Inc. (NASDAQ:NEO), and Clovis Oncology Inc. (NASDAQ:CLVS).


Izotropic Corporation (CSE:IZO)(OTCPK:IZOZF) BREAKING NEWS: Izotropic Corporation has extended the terms of its exclusive global License Agreement with The Regents of the University of California. The amendments under the revised exclusive global License Agreement relate to the formal Commercialization Plan of breast CT technology developed at UC Davis Medical Center in Sacramento, CA. Due to unforeseen delays with patent prosecutions and completing important patent applications and filings, there was mutual desire by the parties to negotiate an extension. The Company now has until January 2027 to execute on the terms agreed to under the Commercialization Plan and expects to meet the terms of the Commercialization Plan under the Licensing Agreement well before this date. In consideration of this extension, a nominal payment of $20,000 per annum will be made until commercialization terms are completed. Extending the commercialization terms and timeline is a material development for the Company and we wish to acknowledge the support and cooperation provided by the Regents of the University of California and UC Davis.


Other related developments from around the markets include:


Hologic Inc. (NASDAQ:HOLX) announced today that the Company will present at these upcoming investor conferences: Cowen and Company’s 40th Annual Healthcare Conference in Boston, MA on Tuesday, March 3 at 8 am ET; The Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 10 at 2:35 pm ET.


Stryker Corporation (NYSE:SYK) will participate in the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at the Boston Marriott Copley Place in Boston, Massachusetts.  Katherine Owen, Vice President, Strategy & Investor Relations, will represent the Company in a presentation scheduled for 10:40 a.m. Eastern Time.


NeGenomics Inc. (NASDAQ:NEO) announced that it plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, February 27, 2020.  The Company has scheduled a web-cast and conference call to discuss their fourth quarter results on Thursday, February 27, 2020 at 8:30 AM EDT. Interested investors should dial (844) 602-0380 (domestic) and (862) 298-0970 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:30 AM EDT on March 5, 2020, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international).


Clovis Oncology Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis’ clinical development programs and regulatory and commercial outlook for 2020. “This is an encouraging time for Clovis, as we launch Rubraca in multiple European countries in the recurrent ovarian cancer maintenance indication and prepare for a potential U.S. approval and launch of Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “We also look forward to initial clinical data from lucitanib combination studies later this year, and initiating clinical development with FAP-2286, our peptide-targeted radiopharmaceutical therapy product candidate. This program, as well as our ongoing discovery collaboration with 3B Pharmaceuticals, provides us an exciting opportunity to be a leader in an important new area of oncology drug development.”


DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates and, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated thirty five hundred dollars for news coverage of current press releases issued by Izotropic Corporation by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact email: – +1(561)325-8757